ARTICLE SUMMARY:
Watchful waiting has hitherto been the best course for smaller abdominal aortic aneurysms, although they are likely to grow, and could unexpectedly rupture. There is hope on the horizon; Nectero recently published two-year FIH data, and Angiolutions emerges with what its founders call a first-in-class mechanobiological device strategy.
An abdominal aortic aneurysm (AAA) is one of the more unsettling diagnoses in vascular medicine: a weakened and gradually enlarging segment of the body’s largest artery that may remain silent for years before suddenly rupturing with catastrophic consequences. Yet despite the potentially fatal nature of rupture, most small AAAs are not immediately repaired. Current clinical practice generally reserves surgical or endovascular intervention for aneurysms that exceed established diameter thresholds—typically around 5.5 cm—or demonstrate rapid expansion. Until then, patients are usually managed with aggressive cardiovascular risk reduction, including smoking cessation, blood pressure and lipid control, and regular imaging surveillance. Monitoring intervals vary by aneurysm size, ranging from every two to three years for smaller aneurysms to every three to six months as they approach the threshold for repair.
This strategy of “watchful waiting” is grounded in evidence showing that early intervention (surgical or endovascular repair) on small aneurysms has not consistently improved survival outcomes compared with surveillance alone. But for many patients, living with an aneurysm under observation can be psychologically burdensome, shaped by the awareness that rupture is frequently sudden and often fatal. The limitations of diameter-based management are also increasingly apparent.
